Investor Relations, Public Relations and Marketing Services for Life Sciences Companies. Founded by industry vets Daniel Eramian and Charles S. Craig
Joined October 2008
- Tweets 149
- Following 453
- Followers 148
- Likes 77
15 Photos and videos
Opus Biotech Comm retweeted
15 Mar 2024
@DiakonosOnc to present poster at #AACR24 on Dendritic Cell Vaccine #immunotherapy for #GBM. Therapies have generated encouraging efficacy and safety in clinical trials to date. Company leadership will be available for meetings. @AACR #cancerresearch #cancer #biopharma
2
1
107
Opus Biotech Comm retweeted
14 Sep 2021
Great news for @NSTherapeutics team. This @NatEyeInstitute @NIH grant will advance our #genetherapy for Age-Related Macular Degeneration
#AMD #opthalomology #retina
bit.ly/3AplXid
1
4
17 May 2021
@hdtbio excited to move toward a vaccine for #HIV-1 with a 3-year grant from @NIH #NIAID. Congrats @KhandharAmit Dir. of Formulation, the PI on this award, and to our LION team for all their hard work. #aids #publichealth #VaccinesWork bit.ly/3eQUFsC
1
3
4
22 Apr 2021
Exciting developments to ultimate make #CovidVaccine available to more people.
@hdtbio is featured in @ScienceMagazine on the challenge of making #COVID19 vaccines with less refrigeration requirements to better serve populations across the globe where refrigeration is in short supply. #COVID19 #covid19vaccine #mrnavaccines
bit.ly/2RLvhLB
19 Apr 2021
Outstanding additions to this company that is doing great things!
19 Apr 2021
@NSTherapeutics announces new clinical advisory board including Michael Singer, MD; Stephen H. Tsang, MD, PhD; Paul Yang, MD, PhD; and Srinivas R Sadda. #retinitispigmentosa #stargardsdisease #AMD #genetherapy #rarediseases #optogenetics bit.ly/2RE9eGC
6 Apr 2021
Great new technology from @hdtbio in this interesting article.
MIT @techreview recently featured @hdtbio CSO Darrick Carter on how HDT's #mRNA #Covid-19 technology can overcome the storage and distribution challenges of current vaccines in use which limit access in developing nations. Read it here: bit.ly/2PIdDrB #VACCINES
5 Mar 2021
Exciting new research! #photonicswest
5 Mar 2021
@NSTherapeutics is at @PhotonicsWest with multiple presentations featuring groundbreaking research in optical gene delivery and opsin-based neuromodulation therapy. @SPIEtweets for details: #https://prn.to/3rnttp3 #optogenetics #genetherapy
1
@hdtbio announces additional $3M as part of seed financing round led by @ZoicCapital for a total raise of $6M. Funds support advancing 3 lead products into clinical trials this year. Details: bit.ly/3u22YqZ #immunotherapy #oncology #vaccines #biotech
2
2
10 Feb 2021
@Opus_Biotech is pleased to partner with @CxPrecisionM, a biotech company developing blood-based diagnostics for early assessment and treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. cxprecisionm.com #Alzheimers #Parkinsons
1
1
1
11 Sep 2020
Really exciting news about a promising treatment for #pancreaticcancer #pancan #cancertreatment #clinicaltrials
10 Sep 2020
@Nanology announces first patient enrolled in expansion of #pancreaticcancer #clinicaltrial. More Details: bit.ly/3ihLXD3
27 Aug 2020
Great news from @NanOlogyLLC about their #bladder cancer program. Check nanology.us for info about programs for #lung cancer #prostatecancer #pancreaticcancer and more. Very interesting and promising.
27 Aug 2020
@NanOlogyLLC Bladder Cancer Trial Enrollment Progress!
We are very excited by the therapeutic potential of NanoDoce in #bladdercancer. Read more:
bit.ly/3jhQ1De
#cancer #clinicaltrial #CancerResearch
Opus Biotech Comm retweeted
30 Dec 2019
@NanOlogyLLC to SF for #JPM2020. Now setting mtgs w/potential partners & investors to discuss clinical progress of our therapeutic drug platform in gastrointestinal, genitourinary, peritoneal, lung & other cancers. Contact marc.iacobucci@dfb.com
nanology.us #pancan
1
2
8 Nov 2019
Go Heather Giles!
7 Nov 2019
Vapogenix attended the Texas Life Science Forum 2019. Wonderful event! Kudos to the organizers.
#TLSF2019 @BioHouston @ricealliance
6 Nov 2019
Exciting news for patients
29 Oct 2019
Today announced results of Phase II trial of our lead product, VPX638, a topical non-opioid, lidocaine-free analgesic. Data reveals VPX638 significantly reduces pain and use of opioids. Read more: bwnews.pr/2NgzHUM #opioidcrisis #painrelief #painmanagement
1
6 Nov 2019
Great opportunity to hear from Houston-based @Vapogenix
5 Nov 2019
Vapogenix is presenting at the Texas Life Science Forum in Houston on Wednesday November 6th, 2019
"Uncovering Strategies for Planning and Executing a Clinical Trial in Australia"
#TXLSF #Pain #Australiaclinicaltrials
12 Feb 2019
Really like this guy!
12 Feb 2019
Tonight @txhbi honors @MDAndersonNews professor and Nobel Prize Winner Jim Allison, PhD
#THBISummit2019
1